High-resolution immunoscintigraphy for in vivo imaging of thyroid cancer by using galectin-3 radio-immunotargeting (Abstract/Poster in atti di convegno)

Type
Label
  • High-resolution immunoscintigraphy for in vivo imaging of thyroid cancer by using galectin-3 radio-immunotargeting (Abstract/Poster in atti di convegno) (literal)
Anno
  • 2008-01-01T00:00:00+01:00 (literal)
Alternative label
  • Signore, A.;Parisella, M. G.; D'Alessandria, C.;Del Prete, F.;Braesch-Andersen, S.; Massari, R.;Trotta, C.;Soluri, A.; Bartolazzi, A.;Scopinaro, F. (2008)
    High-resolution immunoscintigraphy for in vivo imaging of thyroid cancer by using galectin-3 radio-immunotargeting
    in Congress EANM - European Association of Nuclear Medicine 2008, MUNICH (Germany), 11-15/10/2008
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Signore, A.;Parisella, M. G.; D'Alessandria, C.;Del Prete, F.;Braesch-Andersen, S.; Massari, R.;Trotta, C.;Soluri, A.; Bartolazzi, A.;Scopinaro, F. (literal)
Pagina inizio
  • S406 (literal)
Pagina fine
  • S406 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#titoloVolume
  • European Journal of Nuclear Medicine and Molecular Imaging (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 1 (literal)
Note
  • Poster (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1: Policlinico, Rome, ITALY; 2, 3, 9: Nuclear Medicine, 2nd Faculty of Medicine, \"Sapienza\" University, Roma, ITALY; 4, 9: Pathology Research Laboratory St. Andrea Hospital, Roma, ITALY; 5: Mabtech Research Laboratory, Nacka,SWEDEN; 6, 7, 8: Istituto di Ingegneria Biomedica (ISIB) - National Council of Research, Roma, ITALY. (literal)
Titolo
  • High-resolution immunoscintigraphy for in vivo imaging of thyroid cancer by using galectin-3 radio-immunotargeting (literal)
Abstract
  • The  high  prevalence  of  benign  thyroid  nodules  makes  the  preoperative  detection  of  thyroid  cancer comparable to \"looking for a needle in a haystack\". The anti-apoptotic molecule galectin-3  is  preferentially  expressed  in  malignant  thyroid  cells  and  represents  a  potential  target  for  obtaining in vivo imaging of thyroid cancer by using galectin-3 specific radiolabeled antibodies.  Aim of our work was to develop a high-resolution immunoscintigraphy for in vivo detection of  primary and metastatic thyroid cancer based on galectin-3 radio-immunotargeting, which uses a  99mTc-labeled  anti-galectin-3  monoclonal  antibody  and  a  position-sensitive  portable  mini- gamma camera as imaging capture device. Anti-galectin-3 mAb was labelled with high specific  activity using the direct method. QC included SDS-PAGE, HPLC, and several stability tests. To  evaluate the binding specificity of 99mTc-labelled mAb to galectin-3 in vivo, several experiments  were performed. Initially 6 mice bearing galectin-3+ thyroid carcinoma xenografts (ARO-Gal-3+)  were imaged with 100?Ci of 99mTc-labeled mAb (30µg protein) at 1, 3, 6, 9 and 24 hours post  injection using a high-resolution mini-gamma camera. Control was 99mTc-HIG. Then, 6 mice were  transplanted  with  galectin-3+  ARO  cells  (5-8x106  cells)  and  6  mice  were  transplanted  with  galectin-3  knockout  ARO  cells  (ARO-Gal-3-).  Biodistribution  was  studied  in  20  ARO-Gal-3+  xenografted mice injected with 100µCi of 99mTc-labeled mAb and sacrificed at 3, 6, 9, 12, 24  hours p.i. Best visualization of the ARO-Gal-3+ xenografts was obtained between 6 and 12hrs  from injection, whereas ARO-Gal-3- tumors were not detected. Biodistribution showed a rapid  blood clearance of the radiopharmaceutical within 3hrs from injection. Most of the radioactivity  was measured in the liver and kidneys. Finally, a fresh metastatic cervical lymph node, surgically  resected from a patient bearing a papillary thyroid carcinoma, was used as target for 99mTc-anti- Gal-3 mAb binding and imaging ex-vivo. Results of this experiment are showed that the HR- gamma  camera  detected  thyroid  cancer  metastasis  whereas  a  scanty  tumor  uptake  of  the  radiopharmaceutical  was  visible  in  the  control  tumor  section  after  displacement  of  99mTc- labeled-Gal-3 binding by excess of unlabelled mAb. This technology opens new avenues in both imaging and treatment of thyroid cancer with the possibility to extend this application to the  diagnosis and treatment of different galectin-3 positive human malignancies in future.  (literal)
Editore
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
Insieme di parole chiave di
data.CNR.it